Anthropic and OpenEvidence bring medical AI to 100 countries

By Splitfeed EditorialLast updated Sep 26, 2026, 20:18 UTC

On September 22, 2026, Reuters reported exclusively that Anthropic and OpenEvidence had announced a partnership to deploy AI-powered clinical support tools to physicians across approximately 100 countries. The centerpiece of the arrangement is that the service will be provided free of charge to doctors in low- and middle-income nations. The tool is framed as a physician-facing assistant, intended to support clinical decision-making rather than to interact directly with patients. No specific AI model name or detailed contractual terms were disclosed in the available reporting.

The partnership matters because it frames AI deployment not as a premium commercial product but as a form of global health infrastructure, targeting regions where access to specialist medical knowledge is structurally limited. That framing raises questions that are genuinely contested: whether AI can safely substitute for specialist expertise in resource-constrained settings, who bears liability when the tool influences a clinical decision that goes wrong, and whether the free-for-low-income-countries model represents genuine access or a strategy to build market presence in emerging economies. The fact that the tool is doctor-facing rather than patient-facing is a deliberate design choice, but it does not resolve those underlying questions.

The Pro-AI camp has not yet published reactions to this story. Typically, advocates in that camp would be expected to argue that expanding clinical AI to underserved regions could save lives by giving physicians decision support they would otherwise lack entirely, and that free access in poorer nations represents a meaningful commitment to equitable technology distribution. The Anti-AI camp has weighed in, with Kim on Bluesky arguing that Anthropic and OpenEvidence are effectively using people in lower-income nations as test subjects rather than investing in training more doctors in those countries, framing the rollout as exploitation dressed up as philanthropy. The Middle Ground camp has not yet responded, but observers in that position would typically want to know what clinical validation the tool has undergone, what oversight mechanisms exist in each country, and how errors will be monitored and corrected at scale.

The details most likely to shift this debate are any regulatory filings or independent clinical evaluations of the underlying tool, the specific terms Anthropic and OpenEvidence establish with health ministries in participating countries, and whether any formal accountability framework is announced alongside the rollout.